https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-financing-common-stock BiopharmaWatch en 2026-10-08T16:07:00.000Z bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-laboratory-ute-tribe BiopharmaWatch en 2026-10-08T13:26:00.000Z Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-12-million-offering BiopharmaWatch en 2026-10-08T13:22:00.000Z China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering https://www.biopharmawatch.com/news/BFRI/biofrontera-fda-application-ameluz-actinic-keratoses BiopharmaWatch en 2026-10-08T13:22:00.000Z Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body https://www.biopharmawatch.com/news/DARE/dare-bioscience-phase-1-sildenafil-cream-data-smsna BiopharmaWatch en 2026-10-08T13:15:00.000Z Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting https://www.biopharmawatch.com/news/ILMN/illumina-releases-spliceai2-advance-rare-disease-research BiopharmaWatch en 2026-10-08T13:15:00.000Z Illumina releases SpliceAI2 to help advance rare disease research https://www.biopharmawatch.com/news/PHG/philips-global-clinical-advisory-board-oral-care BiopharmaWatch en 2026-10-08T13:00:00.000Z Philips Oral Healthcare Establishes Global Clinical Advisory Board to Help Shape the Future of Oral Care Through Scientific and Clinical Insight https://www.biopharmawatch.com/news/MYGN/sophia-genetics-myriad-genetics-collaboration-prgis BiopharmaWatch en 2026-10-08T13:00:00.000Z SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-financial-restructuring-capital-improvements BiopharmaWatch en 2026-10-08T13:00:00.000Z ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements https://www.biopharmawatch.com/news/IMNN/imunon-participate-investor-conferences-october-2026 BiopharmaWatch en 2026-10-08T13:00:00.000Z IMUNON to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MYGN/myriad-genetics-sophia-genetics-collaboration-prostate-cancer BiopharmaWatch en 2026-10-08T13:00:00.000Z Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology https://www.biopharmawatch.com/news/PRVA/privia-health-third-quarter-2026-results BiopharmaWatch en 2026-10-08T13:00:00.000Z Privia Health to Report Third Quarter 2026 Results on Thursday, November 5 https://www.biopharmawatch.com/news/FEMY/femasys-asrm-2026-exhibit BiopharmaWatch en 2026-10-08T13:00:00.000Z Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo https://www.biopharmawatch.com/news/NAGE/restore-niagen-longevity-month-october BiopharmaWatch en 2026-10-08T12:57:00.000Z Restore Hyper Wellness® and Niagen Bioscience Team Up to Help Americans Age Better This October https://www.biopharmawatch.com/news/NAGE/andrew-shao-awarded-annette-dickinson-trailblazer-award BiopharmaWatch en 2026-10-08T12:32:00.000Z Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN) https://www.biopharmawatch.com/news/IBRX/immunitybio-participate-piper-sandler-oncology-symposium BiopharmaWatch en 2026-10-08T12:30:00.000Z ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium https://www.biopharmawatch.com/news/VIR/vir-biotechnology-fda-fast-track-vir-5500 BiopharmaWatch en 2026-10-08T12:30:00.000Z Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-presents-late-breaking-data-aha-2026 BiopharmaWatch en 2026-10-08T12:30:00.000Z CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 https://www.biopharmawatch.com/news/NXL/nexalin-technology-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-10-08T12:30:00.000Z Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing https://www.biopharmawatch.com/news/BFLY/butterfly-network-q3-2026-financial-results BiopharmaWatch en 2026-10-08T12:05:00.000Z Butterfly Network to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/MDCX/medicus-pharma-three-years-progress-long-term-value BiopharmaWatch en 2026-10-08T12:00:19.000Z Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value https://www.biopharmawatch.com/news/SRRK/scholar-rock-resubmits-apitegromab-maa-ema BiopharmaWatch en 2026-10-08T12:00:00.000Z Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-japanese-patent-allowance BiopharmaWatch en 2026-10-08T12:00:00.000Z bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm https://www.biopharmawatch.com/news/INCY/incyte-third-quarter-financial-results BiopharmaWatch en 2026-10-08T12:00:00.000Z Incyte to Report Third Quarter Financial Results https://www.biopharmawatch.com/news/LTRN/lantern-pharma-thinkequity-conference-2026 BiopharmaWatch en 2026-10-08T12:00:00.000Z Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026 https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-launches-lucyd-aero-smart-glasses BiopharmaWatch en 2026-10-08T12:00:00.000Z Innovative Eyewear, Inc. Launches Lucyd Aero https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-equinox-hfpef-trial-edg-15400 BiopharmaWatch en 2026-10-08T12:00:00.000Z Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 https://www.biopharmawatch.com/news/TECH/bio-techne-expands-gmp-manufacturing-bristol-facility BiopharmaWatch en 2026-10-08T12:00:00.000Z Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-certespetide-pancreatic-cancer-patent BiopharmaWatch en 2026-10-08T12:00:00.000Z Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors https://www.biopharmawatch.com/news/XAIR/beyond-air-preannounces-revenue-q3-2026 BiopharmaWatch en 2026-10-08T12:00:00.000Z Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/ENOV/enovis-third-quarter-2026-results-conference-call BiopharmaWatch en 2026-10-08T12:00:00.000Z Enovis to Host Third Quarter 2026 Results Conference Call on November 5th https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-acg-2026-voquezna-data BiopharmaWatch en 2026-10-08T12:00:00.000Z Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting https://www.biopharmawatch.com/news/ENTX/entera-bio-eb613-phase-3-study-asbmr-2026 BiopharmaWatch en 2026-10-08T12:00:00.000Z Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting https://www.biopharmawatch.com/news/AMRX/amneal-third-quarter-2026-results BiopharmaWatch en 2026-10-08T12:00:00.000Z Amneal to Report Third Quarter 2026 Results on November 3, 2026 https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-appoints-david-zhang BiopharmaWatch en 2026-10-08T12:00:00.000Z Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors https://www.biopharmawatch.com/news/VTRS/viatris-acquires-pacira-biosciences-non-opioid-pain-therapies BiopharmaWatch en 2026-10-08T11:45:00.000Z Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies https://www.biopharmawatch.com/news/CMND/clearmind-patent-publication-japan-dyskinesia-treatment BiopharmaWatch en 2026-10-08T11:32:00.000Z Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-third-quarter-revenue-outlook-2026 BiopharmaWatch en 2026-10-08T11:30:00.000Z Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million https://www.biopharmawatch.com/news/HYPR/hyperfine-announces-q3-2026-results-date BiopharmaWatch en 2026-10-08T11:30:00.000Z Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/AGEN/armenian-marketing-authorization-agenus-bot-bal BiopharmaWatch en 2026-10-08T11:30:00.000Z Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-mstoronto2026-data-presentations BiopharmaWatch en 2026-10-08T11:30:00.000Z TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 https://www.biopharmawatch.com/news/CRON/cronos-group-2026-q3-earnings-call BiopharmaWatch en 2026-10-08T11:30:00.000Z Cronos Group Inc. to Hold 2026 Third Quarter Earnings Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/CNSY/cerenome-florida-blue-cnside-agreement BiopharmaWatch en 2026-10-08T11:30:00.000Z Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests https://www.biopharmawatch.com/news/HELP/helus-pharma-investor-presentation-october-2026 BiopharmaWatch en 2026-10-08T11:30:00.000Z Helus Pharma to Host Investor Presentation on October 21, 2026 https://www.biopharmawatch.com/news/DTIL/precision-biosciences-late-breaking-presentation-aasld-2026 BiopharmaWatch en 2026-10-08T11:01:00.000Z Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026 https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-secures-debt-facility-k2-healthventures BiopharmaWatch en 2026-10-08T11:00:38.000Z X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures https://www.biopharmawatch.com/news/AGIO/agios-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-08T11:00:00.000Z Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET https://www.biopharmawatch.com/news/GKOS/glaukos-exclusive-license-agreement-revopsis-therapeutics BiopharmaWatch en 2026-10-08T11:00:00.000Z Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-technology-vt-symposium-2026 BiopharmaWatch en 2026-10-08T11:00:00.000Z Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026 https://www.biopharmawatch.com/news/HSIC/henry-schein-cfo-leadership-transition BiopharmaWatch en 2026-10-08T11:00:00.000Z Henry Schein Announces Chief Financial Officer Leadership Transition https://www.biopharmawatch.com/news/BLRX/biolinerx-hemispherian-glix1-sno-meeting-2026 BiopharmaWatch en 2026-10-08T11:00:00.000Z BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day https://www.biopharmawatch.com/news/SI/shoulder-innovations-launch-inset-go BiopharmaWatch en 2026-10-08T11:00:00.000Z Shoulder Innovations Initiates Commercial Launch of the InSet® Go https://www.biopharmawatch.com/news/TLRY/tilray-brands-record-q1-fiscal-2027-revenue BiopharmaWatch en 2026-10-08T11:00:00.000Z Tilray Brands Delivers Record Q1 Fiscal 2027 Revenue and Record Q1 Gross Profit, Demonstrating the Power of Its Global Platform, Driven by Double-Digit Year-Over-Year Growth Across International Cannabis, Beverage and Pharmaceutical Distribution https://www.biopharmawatch.com/news/GANX/gain-therapeutics-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-08T11:00:00.000Z Gain Therapeutics to Attend the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-phase-2-study-cln-049-aml BiopharmaWatch en 2026-10-08T11:00:00.000Z Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia https://www.biopharmawatch.com/news/BSEM/biostem-ceo-coo-invest-one-million-stock-options BiopharmaWatch en 2026-10-08T11:00:00.000Z BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options https://www.biopharmawatch.com/news/EDIT/editas-medicine-phase-1-2-trial-approval BiopharmaWatch en 2026-10-08T11:00:00.000Z Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia https://www.biopharmawatch.com/news/ACON/aclarion-clarity-trial-enrollment-criteria-update BiopharmaWatch en 2026-10-08T11:00:00.000Z Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-chardan-healthcare-conference-2026 BiopharmaWatch en 2026-10-08T11:00:00.000Z Lexeo Therapeutics to Participate in the Chardan Healthcare Conference https://www.biopharmawatch.com/news/BMY/zenbexustm-iberdomide-phase-3-results-multiple-myeloma BiopharmaWatch en 2026-10-08T10:59:00.000Z Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3... https://www.biopharmawatch.com/news/DNA/araceli-ginkgo-imagenes-celulares-nebula BiopharmaWatch en 2026-10-08T10:39:00.000Z Araceli Biosciences y Ginkgo Bioworks incorporan la obtención de imágenes celulares al laboratorio de Nebula https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-announces-50-million-private-placement BiopharmaWatch en 2026-10-08T10:30:00.000Z Atrium Therapeutics Announces $50 Million Private Placement https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-fast-track-psv359 BiopharmaWatch en 2026-10-08T10:16:00.000Z Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors https://www.biopharmawatch.com/news/ANGO/angiodynamics-fiscal-year-2027-q1-results BiopharmaWatch en 2026-10-08T10:02:00.000Z AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability https://www.biopharmawatch.com/news/ANGO/angiodynamics-appoints-eric-honroth-ceo BiopharmaWatch en 2026-10-08T10:00:00.000Z AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer https://www.biopharmawatch.com/news/WST/west-third-quarter-2026-conference-call BiopharmaWatch en 2026-10-08T10:00:00.000Z West to Host Third-Quarter 2026 Conference Call https://www.biopharmawatch.com/news/DNA/araceli-ginkgo-cellular-imaging-integration BiopharmaWatch en 2026-10-08T10:00:00.000Z Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop https://www.biopharmawatch.com/news/BHVN/biohaven-licensing-agreement-ono-pharma-bhv-1300 BiopharmaWatch en 2026-10-08T08:00:00.000Z Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease https://www.biopharmawatch.com/news/ADXN/addex-spin-neurosterix-completes-phase-1-clinical-studies-ntx-253 BiopharmaWatch en 2026-10-08T05:00:00.000Z Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia https://www.biopharmawatch.com/news/ARGX/argenx-phase-2-results-fb102-celiac-disease BiopharmaWatch en 2026-10-08T05:00:00.000Z argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease https://www.biopharmawatch.com/news/ARGX/argenx-phase-3-unity-study-update-sjogrens-disease BiopharmaWatch en 2026-10-08T05:00:00.000Z argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease https://www.biopharmawatch.com/news/MDT/medtronic-final-exchange-ratio-minimed-separation BiopharmaWatch en 2026-10-07T21:31:00.000Z Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc. https://www.biopharmawatch.com/news/HIMS/hims-hers-names-jon-franklin-chief-accounting-officer BiopharmaWatch en 2026-10-07T20:17:00.000Z Hims & Hers Names Jon Franklin as Chief Accounting Officer https://www.biopharmawatch.com/news/IQV/iqvia-launches-explorer-commercial-decisions BiopharmaWatch en 2026-10-07T20:15:00.000Z IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions https://www.biopharmawatch.com/news/BAX/baxter-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-07T20:15:00.000Z Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors https://www.biopharmawatch.com/news/IQV/iqvia-launches-life-science-models-predict-clinical-trial-outcomes BiopharmaWatch en 2026-10-07T20:15:00.000Z IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes https://www.biopharmawatch.com/news/PROF/profound-medical-q3-2026-revenue-report BiopharmaWatch en 2026-10-07T20:15:00.000Z Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue https://www.biopharmawatch.com/news/HCSG/prime-healthcare-services-2026-earnings-call BiopharmaWatch en 2026-10-07T20:09:00.000Z Prime Healthcare Services, Inc. Schedules 2026 3rd Quarter Earnings Conference Call https://www.biopharmawatch.com/news/ALEC/alector-virtual-event-abc-enabled-pipeline BiopharmaWatch en 2026-10-07T20:05:00.000Z Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline https://www.biopharmawatch.com/news/GKOS/glaukos-positive-epioxa-results-keratoconus BiopharmaWatch en 2026-10-07T20:05:00.000Z Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-participate-industry-conferences BiopharmaWatch en 2026-10-07T20:05:00.000Z Lifecore Biomedical to Participate at Upcoming Industry Conferences https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-fda-orphan-drug-designation-hppd-sickle-cell BiopharmaWatch en 2026-10-07T20:01:00.000Z vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease https://www.biopharmawatch.com/news/VRTX/vertex-announces-q3-2026-financial-results BiopharmaWatch en 2026-10-07T20:00:00.000Z Vertex to Announce Third Quarter 2026 Financial Results November 2nd https://www.biopharmawatch.com/news/VALN/valneva-ixchiq-uk-market-authorization-update BiopharmaWatch en 2026-10-07T20:00:00.000Z Valneva fait un point sur l’utilisation d’IXCHIQ® au Royaume-Uni https://www.biopharmawatch.com/news/VALN/valneva-update-ixchiq-uk BiopharmaWatch en 2026-10-07T20:00:00.000Z Valneva Provides Update on IXCHIQ® in the United Kingdom https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-positive-phase-2-results-petrelintide BiopharmaWatch en 2026-10-07T17:14:00.000Z Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-first-patient-dosed-phase-2a-trial BiopharmaWatch en 2026-10-07T17:00:00.000Z PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance https://www.biopharmawatch.com/news/PFE/pfizer-tukysa-fda-approval-her2-breast-cancer BiopharmaWatch en 2026-10-07T16:57:00.000Z Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer https://www.biopharmawatch.com/news/GMAB/genmab-extraordinary-general-meeting-2026-remuneration BiopharmaWatch en 2026-10-07T16:17:00.000Z Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members https://www.biopharmawatch.com/news/NVS/novartis-rhapsido-fda-approval-symptomatic-dermographism BiopharmaWatch en 2026-10-07T15:45:00.000Z Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU) https://www.biopharmawatch.com/news/FMS/shervin-korangy-ceo-fresenius-medical-care BiopharmaWatch en 2026-10-07T15:28:00.000Z Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-first-location-boston BiopharmaWatch en 2026-10-07T15:00:00.000Z CVS Pharmacy® celebrates opening of first pharmacy-focused location in Boston area https://www.biopharmawatch.com/news/ASTH/alignment-health-expands-california-2027 BiopharmaWatch en 2026-10-07T15:00:00.000Z Alignment Health Expands to Three New California Counties and Adds Hoag and Astrana Health for 2027 https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-fda-trial-update-danon-disease BiopharmaWatch en 2026-10-07T13:36:00.000Z Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar https://www.biopharmawatch.com/news/AMN/amn-healthcare-q3-2026-earnings-call BiopharmaWatch en 2026-10-07T13:15:00.000Z AMN Healthcare to Hold Third Quarter 2026 Earnings Conference Call on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/AIM/aim-immunotech-strategy-pancreatic-cancer BiopharmaWatch en 2026-10-07T13:14:00.000Z AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-acquires-nexdine-hospitality BiopharmaWatch en 2026-10-07T13:00:00.000Z Healthcare Services Group Announces Acquisition of NEXDINE Hospitality https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-momentum-federal-initiative BiopharmaWatch en 2026-10-07T13:00:00.000Z Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease https://www.biopharmawatch.com/news/TXG/10x-genomics-fred-hutch-collaboration-cancer-research BiopharmaWatch en 2026-10-07T13:00:00.000Z 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers https://www.biopharmawatch.com/news/BCDA/biocardia-presents-cardiamp-hf-ii-trial-design BiopharmaWatch en 2026-10-07T13:00:00.000Z BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting https://www.biopharmawatch.com/news/OPTH/optimi-health-thinkequity-conference-2026 BiopharmaWatch en 2026-10-07T13:00:00.000Z Optimi Health to Present at the ThinkEquity Conference https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-bio-europe-2026-presentation BiopharmaWatch en 2026-10-07T12:48:00.000Z Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-07T12:45:00.000Z Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/CMND/clearmind-advances-dialogue-federal-government-psychedelic-therapies BiopharmaWatch en 2026-10-07T12:40:00.000Z Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA https://www.biopharmawatch.com/news/LTRN/lantern-pharma-taiwan-approvals-phase-2-trial-lp-300 BiopharmaWatch en 2026-10-07T12:31:00.000Z Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC https://www.biopharmawatch.com/news/OSTX/usda-feedback-ost-her2-canine-osteosarcoma BiopharmaWatch en 2026-10-07T12:30:00.000Z OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma https://www.biopharmawatch.com/news/QTI/qt-imaging-breast-acoustic-ct-scanner-premier-agreement BiopharmaWatch en 2026-10-07T12:30:00.000Z QT Imaging’s Breast Acoustic CT™ Scanner Now Available Through National Group Purchasing Agreement with Premier https://www.biopharmawatch.com/news/DXCM/dexcom-q3-2026-earnings-release-call BiopharmaWatch en 2026-10-07T12:30:00.000Z Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-david-liu-cmo BiopharmaWatch en 2026-10-07T12:30:00.000Z Vir Biotechnology Appoints David Liu as Chief Medical Officer https://www.biopharmawatch.com/news/WGS/genedx-advances-genomic-newborn-screening-icoms-2026 BiopharmaWatch en 2026-10-07T12:30:00.000Z GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026 https://www.biopharmawatch.com/news/MRNA/tempus-collaboration-moderna-merck-intismeran BiopharmaWatch en 2026-10-07T12:30:00.000Z Tempus Announces Multi-Year Collaboration with Moderna and Merck https://www.biopharmawatch.com/news/FBLG/fibrobiologics-patent-application-glp1-peptides BiopharmaWatch en 2026-10-07T12:30:00.000Z FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body https://www.biopharmawatch.com/news/QTRX/alzpath-quanterix-licensing-agreement-alzheimers-research BiopharmaWatch en 2026-10-07T12:30:00.000Z ALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research https://www.biopharmawatch.com/news/ABBV/abbvie-temab-a-breakthrough-therapy-designations BiopharmaWatch en 2026-10-07T12:30:00.000Z AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC https://www.biopharmawatch.com/news/HALO/halozyme-injunction-merck-keytruda-sc-europe BiopharmaWatch en 2026-10-07T12:30:00.000Z Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-pancreatic-cancer-data BiopharmaWatch en 2026-10-07T12:30:00.000Z Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib https://www.biopharmawatch.com/news/RNXT/renovorx-prism-tamp-trial-first-patient-enrolled BiopharmaWatch en 2026-10-07T12:30:00.000Z RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial https://www.biopharmawatch.com/news/ONMD/onemednet-signs-mediplexus-channel-partner-korea BiopharmaWatch en 2026-10-07T12:30:00.000Z OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company’s Real World Data Footprint into Korea and the Asia Pacific Region https://www.biopharmawatch.com/news/RARE/ultragenyx-sells-priority-review-voucher-210-million BiopharmaWatch en 2026-10-07T12:30:00.000Z Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-appoints-kaitlyn-tuson BiopharmaWatch en 2026-10-07T12:30:00.000Z Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-cliniquantum-quantum-analysis BiopharmaWatch en 2026-10-07T12:22:00.000Z SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture https://www.biopharmawatch.com/news/ICU/seastar-fda-breakthrough-device-designation-scd-therapy BiopharmaWatch en 2026-10-07T12:16:00.000Z FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-2-3-trials-nsclc BiopharmaWatch en 2026-10-07T12:15:00.000Z MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/CVS/cvs-health-mmr-vaccines-new-york-measles-outbreak BiopharmaWatch en 2026-10-07T12:10:00.000Z CVS Health® reminds New Yorkers that MMR vaccines are available statewide amid measles outbreak https://www.biopharmawatch.com/news/VIVS/vivosim-labs-fda-regulations-non-animal-testing BiopharmaWatch en 2026-10-07T12:05:00.000Z VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods https://www.biopharmawatch.com/news/LABT/lakewood-amendex-positive-preclinical-data-bisphosphocin BiopharmaWatch en 2026-10-07T12:02:00.000Z Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds https://www.biopharmawatch.com/news/QTRX/quanterix-innovita-ivd-access-china-approvals BiopharmaWatch en 2026-10-07T12:00:00.000Z Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals https://www.biopharmawatch.com/news/GEHC/ge-healthcare-third-quarter-2026-results BiopharmaWatch en 2026-10-07T12:00:00.000Z GE HealthCare to announce third quarter 2026 results on October 28, 2026 https://www.biopharmawatch.com/news/NTRA/natera-signatera-guided-study-melanoma BiopharmaWatch en 2026-10-07T12:00:00.000Z Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma https://www.biopharmawatch.com/news/LPCN/lipocine-health-canada-approval-tlando BiopharmaWatch en 2026-10-07T12:00:00.000Z Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy https://www.biopharmawatch.com/news/IMUX/immunic-present-new-data-vidofludimus-calcium-mstoronto2026 BiopharmaWatch en 2026-10-07T12:00:00.000Z Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-positive-data-mst2026 BiopharmaWatch en 2026-10-07T12:00:00.000Z Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026 https://www.biopharmawatch.com/news/PCRX/pacira-caregiver-survey-postsurgical-recovery BiopharmaWatch en 2026-10-07T12:00:00.000Z Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home https://www.biopharmawatch.com/news/AKBA/akebia-investor-meetings-kidney-health-forum BiopharmaWatch en 2026-10-07T12:00:00.000Z Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-warrant-purchase-offer BiopharmaWatch en 2026-10-07T12:00:00.000Z Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants https://www.biopharmawatch.com/news/ARWR/arrowhead-fda-star-pilot-plozasiran BiopharmaWatch en 2026-10-07T11:30:00.000Z Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia https://www.biopharmawatch.com/news/KURA/caspian-kura-investor-webcast-ko-7246-data BiopharmaWatch en 2026-10-07T11:15:00.000Z Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes https://www.biopharmawatch.com/news/QDEL/quidelortho-appoints-sanjeev-sharma-investor-relations BiopharmaWatch en 2026-10-07T11:13:00.000Z QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations https://www.biopharmawatch.com/news/USNA/usana-partnership-university-utah-athletics BiopharmaWatch en 2026-10-07T11:06:00.000Z USANA Health Sciences and University of Utah Athletics Announce New Partnership https://www.biopharmawatch.com/news/KIDS/orthopediatrics-launches-knee-tractorfix-bracing BiopharmaWatch en 2026-10-07T11:05:00.000Z OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-upcoming-presentations-ms-data-mstoronto2026 BiopharmaWatch en 2026-10-07T11:05:00.000Z Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026 https://www.biopharmawatch.com/news/GKOS/glaukos-third-quarter-2026-results-release BiopharmaWatch en 2026-10-07T11:00:00.000Z Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28 https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-phase-2a-trial-glyphago BiopharmaWatch en 2026-10-07T11:00:00.000Z Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-nanopulse-af-study-enrollment-target BiopharmaWatch en 2026-10-07T11:00:00.000Z Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-strengthens-ip-portfolio BiopharmaWatch en 2026-10-07T11:00:00.000Z Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States https://www.biopharmawatch.com/news/KOD/kodiak-sciences-aao-2026-presentation BiopharmaWatch en 2026-10-07T11:00:00.000Z Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026 https://www.biopharmawatch.com/news/DHR/danaher-ai-autonomous-lab-launch BiopharmaWatch en 2026-10-07T11:00:00.000Z Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-strategic-process-cvkd BiopharmaWatch en 2026-10-07T11:00:00.000Z Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics https://www.biopharmawatch.com/news/BLLN/billiontoone-northstar-response-cancer-monitoring-study BiopharmaWatch en 2026-10-07T11:00:00.000Z BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q3-2026-results BiopharmaWatch en 2026-10-07T11:00:00.000Z Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 https://www.biopharmawatch.com/news/ARVN/arvinas-arv-102-parkinsons-phase-1-trial-data BiopharmaWatch en 2026-10-07T11:00:00.000Z Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease https://www.biopharmawatch.com/news/NVS/novartis-ms-innovation-remibrutinib-kesimpta-data BiopharmaWatch en 2026-10-07T11:00:00.000Z Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-fda-aligned-nams-strategy BiopharmaWatch en 2026-10-07T11:00:00.000Z VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy https://www.biopharmawatch.com/news/RMTI/rockwell-medical-best-workplaces-2026 BiopharmaWatch en 2026-10-07T10:26:00.000Z Rockwell Medical Ranked No. 16 on the 2026 Fortune ‘Best Workplaces in Manufacturing & Production’ List https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-nanets-2026-presentation BiopharmaWatch en 2026-10-07T10:16:00.000Z Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium https://www.biopharmawatch.com/news/EW/edwards-lifesciences-earnings-conference-call-november-2026 BiopharmaWatch en 2026-10-07T10:00:00.000Z Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 https://www.biopharmawatch.com/news/BSX/boston-scientific-appoints-joseph-fitzgerald-coo BiopharmaWatch en 2026-10-07T10:00:00.000Z Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer https://www.biopharmawatch.com/news/TDOC/teladoc-health-expands-solo-platform-ai-capabilities BiopharmaWatch en 2026-10-07T10:00:00.000Z Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery https://www.biopharmawatch.com/news/COSM/cosmos-health-reports-record-revenue-2026 BiopharmaWatch en 2026-10-07T09:30:00.000Z Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million https://www.biopharmawatch.com/news/MODD/modular-medical-webull-webinar-october-2026 BiopharmaWatch en 2026-10-07T08:00:00.000Z Modular Medical to Present at the Webull Emerging & Innovative Companies Webinar on October 14th https://www.biopharmawatch.com/news/OCS/oculis-licaminlimab-aao-2026 BiopharmaWatch en 2026-10-07T06:00:00.000Z Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-phase-1b-2-study-bexobrutideg-cll BiopharmaWatch en 2026-10-07T05:00:00.000Z Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia https://www.biopharmawatch.com/news/PCVX/vaxcyte-public-offerings-common-stock-notes BiopharmaWatch en 2026-10-07T02:48:00.000Z Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes https://www.biopharmawatch.com/news/YDES/yd-bio-eg-biomed-ai-cancer-risk-tool-launch BiopharmaWatch en 2026-10-07T02:32:39.000Z YD Bio and EG BioMed Launch AI Cancer Risk Assessment Tool Covering 10 Cancer Types https://www.biopharmawatch.com/news/NNVC/nanoviricides-presentation-niba-investment-conference-2026 BiopharmaWatch en 2026-10-07T00:00:00.000Z NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 https://www.biopharmawatch.com/news/HIMS/hims-hers-health-securities-fraud-class-action BiopharmaWatch en 2026-10-06T21:33:07.977Z Hims & Hers Health (NYSE: HIMS) Faces Securities Fraud Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower https://www.biopharmawatch.com/news/HYFT/mindwalk-ai-biological-context-layer BiopharmaWatch en 2026-10-06T20:47:00.000Z MindWalk (NASDAQ : HYFT) : l'IA d'entreprise a trouvé sa couche ontologique, la biologie en a besoin d'une ancrée dans la fonction biologique https://www.biopharmawatch.com/news/BLCO/bausch-lomb-advances-oral-treatment-dry-amd BiopharmaWatch en 2026-10-06T20:30:00.000Z Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting https://www.biopharmawatch.com/news/EHC/encompass-health-bangor-hospital-opening-maine BiopharmaWatch en 2026-10-06T20:30:00.000Z Encompass Health Rehabilitation Hospital of Bangor now open in Maine https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-q3-2026-results-announcement BiopharmaWatch en 2026-10-06T20:30:00.000Z Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026 https://www.biopharmawatch.com/news/ALVO/alvotech-lotte-biologics-manufacturing-agreement BiopharmaWatch en 2026-10-06T20:30:00.000Z Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply https://www.biopharmawatch.com/news/NVST/envista-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-06T20:15:00.000Z Envista Schedules Third Quarter 2026 Earnings Call https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-inducement-awards-20261006 BiopharmaWatch en 2026-10-06T20:15:00.000Z Crescent Biopharma Announces Grants of Inducement Awards https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-secures-credit-facility-150-million BiopharmaWatch en 2026-10-06T20:12:00.000Z Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital https://www.biopharmawatch.com/news/ARAY/accuray-stockholder-approval-financing-director BiopharmaWatch en 2026-10-06T20:10:00.000Z Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-evaluate-strategic-alternatives BiopharmaWatch en 2026-10-06T20:05:31.000Z Caribou Biosciences to Evaluate Strategic Alternatives https://www.biopharmawatch.com/news/QGEN/qiagen-ai-powered-bioinformatics-research-drug-discovery BiopharmaWatch en 2026-10-06T20:05:00.000Z QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery https://www.biopharmawatch.com/news/BFLY/bridge-neurotech-butterfly-network-partnership-bci BiopharmaWatch en 2026-10-06T20:05:00.000Z Bridge Neurotech and Butterfly Network Announce Partnership to Develop Fully Non-Invasive Brain-Computer Interface https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-mze829-mze782-asn-kidney-week-2026 BiopharmaWatch en 2026-10-06T20:05:00.000Z Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/EQ/equillium-poster-presentation-la-jolla-immunology-conference BiopharmaWatch en 2026-10-06T20:05:00.000Z Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-scientific-advisory-board-creation BiopharmaWatch en 2026-10-06T20:05:00.000Z Harvard Bioscience Announces Creation of Scientific Advisory Board https://www.biopharmawatch.com/news/IVA/inventiva-abstracts-aasld-liver-meeting-2026 BiopharmaWatch en 2026-10-06T20:05:00.000Z Inventiva présentera plusieurs abstracts scientifiques lors de l’AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/IVA/inventiva-present-scientific-abstracts-aasld-2026 BiopharmaWatch en 2026-10-06T20:05:00.000Z Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/HALO/halozyme-expands-collaboration-with-argenx-enhanze BiopharmaWatch en 2026-10-06T20:05:00.000Z Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-fda-alignment-enable-2-trial BiopharmaWatch en 2026-10-06T20:05:00.000Z Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia https://www.biopharmawatch.com/news/IMNM/immunome-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261006 BiopharmaWatch en 2026-10-06T20:02:00.000Z Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-granting-new-hire-inducement-awards BiopharmaWatch en 2026-10-06T20:02:00.000Z Achieve Life Sciences Announces Granting of New Hire Inducement Awards https://www.biopharmawatch.com/news/BBIO/bridgebio-acoramidis-data-hfsa-annual-meeting-2026 BiopharmaWatch en 2026-10-06T20:01:00.000Z BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 https://www.biopharmawatch.com/news/BBIO/bridgebio-present-evidence-phase-3-calibrate-trial-encaleret BiopharmaWatch en 2026-10-06T20:01:00.000Z BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting https://www.biopharmawatch.com/news/EVGN/evogene-pure-capital-agreement-board-reconstitution BiopharmaWatch en 2026-10-06T20:00:00.000Z Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors https://www.biopharmawatch.com/news/INAB/in8bio-inducement-grant-nasdaq-rule-5635c4 BiopharmaWatch en 2026-10-06T20:00:00.000Z IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CDRE/veeva-dqs-nettoie-donnees-participants-etudes BiopharmaWatch en 2026-10-06T18:52:00.000Z Veeva DQS nettoie les données de plus d'un million de participants dans le cadre de plus de 1 000 études